Thyrotropin-releasing hormone: abundance in the skin of the frog, Rana pipiens.

Thyrotropin-releasing hormone, a hypothalamic tripeptide that stimulates the secretion of pituitary thyroid-stimulating hormone in mammalian species and is widely distributed throughout the brain of vertebrates, is present in the skin of the frog (Rana pipiens) in concentrations twice that found in the hypothalamus of this amphibian. A skin extract shows biologic activity appropriate to its immunoreactive content. Apart from the brain and spinal cord, immunoreactive thyrotropin-releasing hormone is found only in the blood and retina in significant concentrations. The results imply that frog skin is a huge endocrine organ that synthesizes and secretes this hormone.

Immunohistochemical localization in the rat brain of the precursor for thyrotropin-releasing hormone.

A rabbit antiserum to a peptide sequence present in the precursor for thyrotropin-releasing hormone (proTRH), deduced from cloned amphibian-skin complementary DNA, was raised by immunization with the synthetic decapeptide Cys-Lys-Arg-Gln-His-Pro-Gly-Lys-Arg-Cys (proTRH-SH). Immunohistochemical studies on rat brain tissue showed staining of neuronal perikarya in the parvicellular division of the paraventricular nucleus of the hypothalamus and the raphe complex of the medulla, identical to that already described for thyrotropin-releasing hormone (TRH). Immunostaining was abolished by preincubation with proTRH-SH (10(-6)M) but not TRH (10(-5)M). Both TRH precursor and TRH were located in neurons of the paraventricular nucleus. However, in contrast to the findings for TRH, no staining was observed in axon terminals of the median eminence. These results suggest that a TRH precursor analogous to that reported in frog skin is present in the rat brain and that TRH in the mammalian central nervous system is a product of ribosomal biosynthesis.

Thyrotropin-releasing hormone precursor: characterization in rat brain.

To characterize the precursor of mammalian thyrotropin-releasing hormone (TRH), a rat hypothalamic lambda gt11 library was screened with an antiserum directed against a synthetic peptide representing a portion of the rat TRH prohormone. The nucleotide sequence of the immunopositive complementary DNA encoded a protein with a molecular weight of 29,247. This protein contained five copies of the sequence Gln-His-Pro-Gly flanked by paired basic amino acids and could therefore generate five TRH molecules. In addition, potential cleavage sites in the TRH precursor could produce other non-TRH peptides, which may be secreted. In situ hybridization to rat brain sections demonstrated that the pre-proTRH complementary DNA detected neurons concentrated in the parvocellular division of the paraventricular nucleus, the same location as cells detected by immunohistochemistry. These findings indicate that mammalian TRH arises by posttranslational processing of a larger precursor protein. The ability of the TRH prohormone to generate multiple copies of the bioactive peptide may be an important mechanism in the amplification of hormone production.

Thyroid hormone regulates TRH biosynthesis in the paraventricular nucleus of the rat hypothalamus.

Thyroid hormone is important in the regulation of synthesis and secretion of thyroid-stimulating hormone (TSH) in the anterior pituitary, but its role in the control of hypothalamic thyrotropin-releasing hormone (TRH) is controversial. To determine whether thyroid hormone regulates the function of TRH in the hypothalamic tuberoinfundibular system, a study was made of the effect of hypothyroidism on thyrotropin-releasing hormone messenger RNA (proTRH mRNA) and TRH prohormone in the rat paraventricular nucleus. Extracts of rat hypothalamic paraventricular nucleus were examined by quantitative Northern blot analysis, and coronal sections of rat brain were examined by in situ hybridization histochemistry and immunocytochemistry. A nearly twofold increase in proTRH mRNA was observed in hypothyroid animals; this increase could be obliterated by levothyroxine treatment, suggesting an inverse relation between circulating thyroid hormone and proTRH mRNA. In situ hybridization showed that this response occurred exclusively in medial parvocellular neurons of the paraventricular nucleus. A simultaneous increase in proTRH mRNA and immunoreactive TRH prohormone in this region suggests that hypothyroidism induces both transcription and translation of the TRH prohormone in the paraventricular nucleus.

Thyrotropin-releasing hormone in the pancreas and brain of the rat is regulated by central noradrenergic and dopaminergic pathways.

These studies have been undertaken to evaluate the role of the brain noradrenergic and dopaminergic pathways in the regulation of the secretion of thyrotropin-releasing hormone (TRH) in the central nervous system (CNS) and pancreas of the neonatal rat. When CNS stores of norepinephrine (NE) were selectively reduced by the subcutaneous administration of the dopamine-beta-hydroxylase inhibitor FLA-63, TRH concentrations were significantly reduced throughout the brain. However, when CNS stores of both NE and dopamine (DA) were depleted by the subcutaneous administration of the tyrosine hydroxylase inhibitor alpha-methyl-rho-tyrosine (alpha-MT), TRH concentrations in the brain were not significantly altered.FLA-63 and alpha-MT did not significantly reduce pancreatic catecholamine concentrations, indicating that in the basal state, these agents predominantly deplete central catecholamine stores. Nevertheless, pancreatic TRH concentrations were markedly reduced by FLA-63, and this effect was significantly attenuated by the simultaneous intracerebroventricular (icv) administration of NE. In contrast to the effects of FLA-63, alpha-MT caused a significant increase in pancreatic TRH concentrations, and this effect was significantly lessened by icv DA. To determine whether the sympathetic nervous system might be one route by which these central effects are mediated, a chemical sympathectomy was induced with guanethidine. This treatment selectively reduced pancreatic concentrations of NE, and caused a marked increase in pancreatic TRH concentrations. FROM THESE OBSERVATIONS, WE CONCLUDE THE FOLLOWING: (a) within the central nervous system, both NE and DA are involved in regulating brain TRH secretion or biosynthesis, and the direction of action of these two neurotransmitters appears to be opposite; (b) pancreatic TRH secretion or biosynthesis is also controlled by the brain noradrenergic and dopaminergic systems, and the net effects of each of these pathways appears to be opposite; (c) at least one route by which impulses from the brain may travel and modulate pancreatic TRH secretion or biosynthesis is by the sympathetic nervous system.

Thyrotropin-releasing hormone in the systemic circulation of the neonatal rat is derived from the pancreas and other extraneural tissues.

Thyrotropin-releasing hormone immunoreactivity (IR-TRH) has been detected in the circulation of the neonatal rat. This immunoreactivity was demonstrated in purified ethanol extracts of plasma, and was indistinguishable from synthetic TRH using radioimmunoassay and chromatographic criteria. To determine the source of the circulating IR-TRH, tissue concentrations of TRH were analyzed during maturation of the rat. These studies revealed that during the first 10 d of life, the pancreas contained the greatest concentration of IR-TRH of any organ (pancreas, 289+/-35 pg/mg; hypothalamus, 13+/-3 pg/mg, day 5). Thereafter, pancreatic IR-TRH concentrations declined progressively while hypothalamic concentrations gradually increased (pancreas, 1.2+/-0.2 pg/mg; hypothalamus, 365+/-54 pg/mg, adult rat). IR-TRH was also found throughout the gastrointestinal tract but was not detected in the liver, spleen, kidney, or heart. IR-TRH from the pancreas and gastrointestinal tract gave radio-immunoassay binding displacement curves that were parallel to a curve generated with synthetic TRH, and co-migrated with synthetic TRH on Sephadex G-10 and high performance liquid chromatography. In addition, IR-TRH from purified pancreatic extracts was biologically active in that it released thyrotropin and prolactin from rat adenohypophysial cells maintained in monolayer culture. When a total pancreatectomy was performed on the 5th d of life of the rat, mean plasma TRH concentrations were significantly decreased 3 h afterwards (84+/-9 vs. 63+/-7 pg/ml, P < 0.05). Neither the TRH concentrations in the brain, hypothalamus, or gastrointestinal tract, nor the pituitary-thyroid axis were affected by the pancreatectomy. However, mean plasma TRH concentrations remained unaltered 3 h after removal of the hypothalamus and extrahypothalamic brain. FROM THESE RESULTS WE CONCLUDE THE FOLLOWING: (a) the TRH immunoreactivity in the circulation, pancreas, and gastrointestinal tract of the neonatal rat is indistinguishable from synthetic TRH; (b) pancreatic secretion provides a significant contribution to the IR-TRH in plasma, and a proportion of the circulating IR-TRH is derived from other extraneural sites. These findings therefore imply that alterations in hypothalamic and extrahypothalamic brain secretion of TRH are not reflected by changes in levels of this tripeptide in the systemic circulation.

Histidyl-proline diketopiperazine (His-Pro DKP) immunoreactivity is present in the glucagon-containing cells of the human fetal pancreas.

Histidyl-proline diketopiperazine (His-Pro DKP) cells in the pancreas of human fetuses aged between 12 and 19 wk were localized by the indirect antibody-enzyme method on semithin sections. To study their fine structure, two techniques were used: a superimposition technique consisting of comparison of the same cells in semithin and electron microscopic preparations, and an immunocytochemical technique on ultrathin sections using the unlabeled antibody peroxidase-antiperoxidase method. Our results show that (a) the same cells are positive for both His-Pro DKP and glucagon/glicentin, (b) His-Pro DKP immunoreactive cells possess extremely electron-opaque secretory granules, implying that these cells correspond to the A cells, and (c) His-Pro DKP immunoreactivity is found over the secretory granules. We hypothesize that the two peptides His-Pro DKP and thyrotropin-releasing hormone (TRH) have independent origins, since TRH is found in the B cells.

Association of cocaine- and amphetamine-regulated transcript-immunoreactive elements with thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus and its role in the regulation of the hypothalamic-pituitary-thyroid axis during fasting.

Because cocaine- and amphetamine-regulated transcript (CART) coexists with alpha-melanocyte stimulating hormone (alpha-MSH) in the arcuate nucleus neurons and we have recently demonstrated that alpha-MSH innervates TRH-synthesizing neurons in the hypothalamic paraventricular nucleus (PVN), we raised the possibility that CART may also be contained in fibers that innervate hypophysiotropic thyrotropin-releasing hormone (TRH) neurons and modulate TRH gene expression. Triple-labeling fluorescent in situ hybridization and immunofluorescence were performed to reveal the morphological relationships between pro-TRH mRNA-containing neurons and CART- and alpha-MSH-immunoreactive (IR) axons. CART-IR axons densely innervated the majority of pro-TRH mRNA-containing neurons in all parvocellular subdivisions of the PVN and established asymmetric synaptic specializations with pro-TRH neurons. However, whereas all alpha-MSH-IR axons in the PVN contained CART-IR, only a portion of CART-IR axons in contact with pro-TRH neurons were immunoreactive for alpha-MSH. In the medial and periventricular parvocellular subdivisions of the PVN, CART was co-contained in approximately 80% of pro-TRH neuronal perikarya, whereas colocalization with pro-TRH was found in <10% of the anterior parvocellular subdivision neurons. In addition, >80% of TRH/CART neurons in the periventricular and medial parvocellular subdivisions accumulated Fluoro-Gold after systemic administration, suggesting that CART may serve as a marker for hypophysiotropic TRH neurons. CART prevented fasting-induced suppression of pro-TRH in the PVN when administered intracerebroventricularly and increased the content of TRH in hypothalamic cell cultures. These studies establish an anatomical association between CART and pro-TRH-producing neurons in the PVN and demonstrate that CART has a stimulatory effect on hypophysiotropic TRH neurons by increasing pro-TRH gene expression and the biosynthesis of TRH.

Abundance of immunoreactive thyrotropin-releasing hormone-like material in the alfalfa plant.

Immunoreactive TRH (IR-TRH) is found in high concentrations (157 +/- 6 ng/g) in extracts of a plant, alfalfa. On high performance liquid chromatography (HPLC), most alfalfa TRH showed an increased retention time compared to synthetic TRH. Since the plant extract eluted after synthetic TRH on both Sephadex G-10 and Biogel P-2 chromatography, it does not appear to be an aggregate or a "big" TRH. Incubation with rat serum caused degradation of alfalfa TRH at a rate similar to synthetic TRH. Since the antibody against TRH is highly specific for the N and C terminal ends of the molecule, a point change at the His could explain the nature of alfalfa TRH. The biologic function of material resembling a mammalian hypothalamic releasing factor in this location is unknown, but its presence in the plant kingdom may have evolutionary significance.

Regulation of thyrotropin-releasing hormone secretion from frog skin.

The regulation of TRH secretion from skin fragments of the leopard frog, Rana pipiens, was examined under various conditions. TRH secretion is under dual neurotransmitter control with stimulatory noradrenergic and inhibitory dopaminergic components; other neurotransmitters were generally without effect. Membrane-depolarizing conditions required the presence of calcium to cause TRH release consistent with a stimulus-secretion coupling mechanism. However, the norepinephrine-stimulated response appeared to be independent of external Ca++. TRH secretion was unresponsive to somatostatin, T3, and dibutyryl cAMP, substances which may affect TRH secretion in the mammalian hypothalamus. Anuran skin is a complex secretory tissue, but the presence of large quantities of TRH and other biologically active neuropeptides makes this tissue an attractive model to study the regulation of neuropeptide secretion.

Thyrotropin-releasing hormone and c-fos/c-jun genes are colocalized in rat anterior pituitary cells: stimulation of transcription by glucocorticoids.

We recently reported that glucocorticoids (GC) enhance the level of TRH peptide and messenger RNA in anterior pituitary cells. However, the regulating mechanism is as yet unclear. The protooncogenes c-fos/c-jun belong to the class of immediate early genes that are activated in neurons by a variety of stimuli, including GC. Fos protein acts as an intracellular third messenger, regulating gene transcription of neurotransmitters. To determine whether c-fos/c-jun are involved in regulating the effect of GC on TRH in rat anterior pituitary cells, the coexpression and nuclear transcription activity of TRH and c-fos/c-jun after dexamethasone (DEX) stimulation (7 days) were investigated. The double labeled in situ hybridization results demonstrated that TRH and c-fos/c-jun are coexpressed in anterior pituitary cells and that DEX (10(-8) M) enhanced the cell intensity for TRH and c-fos/c-jun. The mean cell intensity of treatment vs. control was 2.4-fold for TRH, 1.4-fold for c-fos, and 1.4-fold for c-jun (n = 24; P < 0.01). The Northern blot analysis also showed that DEX increased the messenger RNA level of TRH 5.1-fold (n = 4; P < 0.01), that of c-fos 1.8-fold (n = 5; P < 0.01), and that of c-jun 4.2-fold (n = 4; P < 0.01). The nuclear run-on analysis indicated that DEX increased the nuclear transcription activity of TRH 3.3-fold, that of c-jun 3.2-fold, and that of c-fos 3-fold (n = 3; P < 0.01) vs. the control value. The coexpression of TRH and c-fos/c-jun in anterior pituitary cells as well as the enhancement of transcription after DEX treatment raise the possibility that c-fos/c-jun could mediate the effect of GC on TRH gene transcriptional activity.

Immunohistochemical localization of thyrotropin-releasing hormone in the rat hypothalamus and pituitary.

The distribution of immunoreactive TRH in the rat hypothalamus and pituitary was demonstrated using the peroxidase-antiperoxidase technique after rapid fixation of the rat brain with 5% acrolein. Widespread reaction product was identified in neuronal processes throughout the hypothalamus, with dense labeling in the median eminence, dorsomedial nucleus, parvocellular division of the paraventricular nucleus, perifornical region, periventricular nucleus, and organum vasculosum of the lamina terminalis. A striking accumulation of immunoreactive TRH was also noted throughout the posterior pituitary, where fibers appeared to terminate in grape-like swellings. Peroxidase-positive perikarya were best seen after colchicine pretreatment and were distributed in many regions of the hypothalamus. The greatest density of immunoreactive neurons was in the suprachiasmatic preoptic nucleus, parvocellular subdivision of the paraventricular nucleus, perifornical region, dorsomedial nucleus, and baso-lateral hypothalamus. These data are consistent with the role of TRH as a hypophysiotropic hormone, a regulator of the posterior pituitary, and a neurotransmitter or neuromodulator of neurons in other regions of the hypothalamus.

Thyrotropin releasing hormone (TRH) in pineal and hypothalamus of the frog: effect of season and illumination.

The influence of photo-illumination and season on the pineal and hypothalamic content of TRH in the leopard frog (Rana pipiens) was studied. Animals (4-6 in each group) were exposed to constant light or darkness for 72 h and then sacrificed. The pineal and hypothalamus from each frog were extracted for TRH measurement by radioimmunoassay. The experiment was performed in spring, autumn, early winter and mid-winter. In early winter, mid-winter and spring the pineal content of TRH ranged from 0.14-0.70 ng. Significant differences between groups due to season and illumination were recorded. In autumn, mean levels of TRH were 12.95 ng (dark exposed) and 4.19 ng (light exposed)-values 10-20 times higher than at other times of the year (P less than 0.001). The hypothalamic content of TRH ranged from 11.4 ng in spring to 19.5 ng in autumn. Seasonal differences were present, but no effect of light or darkness was found. There was no definite relation between the TRH levels in hypothalamus and pineal. The alteration in pineal and hypothalamic TRH produced by season, and the effect of illumination on pineal TRH content, support the view that TRH has a neuronal function in vertebrates, possibly as a neurotransmitter.

Glucocorticoids stimulate thyrotropin-releasing hormone gene expression in cultured hypothalamic neurons.

Although there is much evidence indicating that glucocorticoids (GC) inhibit the hypothalamic-pituitary-thyroid axis in both rat and man in vivo, there have been no previous studies on the direct effect of GC on hypothalamic TRH neurons in vitro. In this laboratory, we developed fetal rat (day 17) diencephalic neuronal cultures in the presence of 5'-bromo-2-deoxyuridine, a cell-differentiating agent that stimulates TRH gene expression. In 12 separate experiments, dexamethasone (Dex) induced a 2.2-fold increase in TRH content vs. the control value (P < 0.01). Dex (10(-8)M) enhanced TRH messenger RNA (mRNA) 1.6-fold (n = 75 wells; P < 0.01) by nonisotopic in situ hybridization. On Northern blot analysis using a 32P-labeled complementary RNA probe, TRH mRNA was enhanced 3-fold (n = 4; P < 0.01). Nuclear run-on analysis revealed that Dex enhanced transcription 7.7 fold (n = 3; P < 0.01). We conclude that 1) Dex stimulates the expression of TRH peptide and TRH mRNA in cultured hypothalamic neurons; 2) the increase in TRH mRNA results (at least in part) from enhanced transcription; and 3) the reported in vivo depression of TRH in the paraventricular nucleus after GC stimulation suggests that this effect must be mediated indirectly on the TRH neuron.

Immunolocalization of the thyrotropin-releasing hormone prohormone in the rat central nervous system.

The distribution of immunoreactive TRH prohormone in the rat central nervous system was studied by immunocytochemistry using an antiserum raised against a synthetic decapeptide hypothesized to represent a portion of the mammalian TRH precursor protein. Reaction product was identified in several regions of the brain in a distribution typical of that previously described for the tripeptide. In contrast to TRH, however, immunoreactive pro-TRH was largely confined to neuronal perikarya and only rarely seen in axons or axon terminals. In addition, immunoreactive pro-TRH was present in portions of the telencephalon and brainstem where TRH has not previously been described in neurons by immunocytochemistry. These studies indicate that in most regions of the brain the TRH prohormone is rapidly processed within the cell soma and not during axonal transport, and raise the possibility that in certain regions of the brain processing of the prohormone may be to non-TRH peptides, which may be of biological importance.

Thyrotropin-releasing hormone release from rat pancreas is stimulated by serotonin but inhibited by carbachol.

Immunoreactive TRH (IR-TRH) has been found in the mammalian pancreas, with several studies documenting high concentrations in the late fetal/early neonatal period. As the factors regulating pancreatic TRH synthesis and release have not been fully explored, we developed a monolayer culture system of dissociated fetal/neonatal rat pancreatic cells to study the release of TRH from the mammalian pancreas. IR-TRH was detected in the culture medium and the IR material appeared authentic based on parallelism with synthetic TRH in RIA and retention time on HPLC. Potassium-induced depolarization (60 mM KCl) resulted in a 170% increase in TRH release compared to that by the Krebs-Ringer bicarbonate control (P less than 0.05). Serotonin stimulated TRH release, with the maximal effect seen with 10(-6) M (130% increase compared to control; P less than 0.05). Carbachol resulted in a dose-dependent inhibition of TRH release (57% inhibition of release at 10(-8) M; P less than 0.01 compared to control). There was no effect on release with norepinephrine, epinephrine, dopamine, gamma-aminobutyric acid, or histamine. We conclude the following. 1) Authentic TRH is secreted by fetal/neonatal rat pancreatic cells in culture. 2) The secretion of TRH is stimulated by potassium-induced depolarization in a calcium-dependent manner, suggesting a classic neurosecretory process of release. 3) The secretion of pancreatic TRH may be under specific neurotransmitter control, with serotonin stimulating and acetylcholine inhibiting release of the tripeptide.

Identification and characterization of thyrotropin-releasing hormone precursor peptides in rat brain.

The sequence of rat hypothalamic pro-TRH, deduced by sequencing of cDNA, contains five copies of the TRH progenitor sequence Gln-His-Pro-Gly flanked by paired basic amino acid sequences. The TRH prohormone also contains leader and trailer sequences and four intervening sequences. We have developed two RIAs against synthetic peptides corresponding to sequences within the deduced pro-TRH sequence and have used these assays to identify and partially characterize four pro-TRH-derived peptides distinct from TRH in extracts of rat brain tissue. Two of these peptides contain incompletely processed TRH sequences; the other two peptides are probably derived from the N-terminal leader sequence. The presence of these authentic pro-TRH-derived peptides indicates that pro-TRH may give rise to a family of peptides other than TRH, some of which may be of biological significance.

Immunocytochemical distribution in rat brain of putative peptides derived from thyrotropin-releasing hormone prohormone.

Processing of the TRH prohormone (Pro-TRH), a protein of approximately 26,000 mol wt, could yield 5 copies of TRH, as well as extended forms of TRH and several other non-TRH peptides. To determine whether some of these peptides are formed and transported by axons in the rat brain, we used antiserum to synthetic peptides corresponding to portions of pro-TRH. These included the N-tyrosyl analogs [Tyr0]prepro-TRH-(25-50) (pYE27) and [Tyr1]prepro-TRH-(53-74) (pYT22) contained within the N-terminal flanking region of the prohormone, the N-tyrosyl analog [Tyr0]prepro-TRH-(165-186) (pYS23), expanding the fourth progenitor sequence of TRH in the midportion of the prohormone, and the synthetic peptide pAC12 corresponding to the first 12 amino acids of the C-terminal flanking region or prepro-TRH-(208-219). All antisera showed staining in neuronal perikarya and processes in all regions of the brain previously demonstrated to immunostain for TRH, including dense innervation of the external zone of the median eminence. In addition, these antisera immunostained regions of the brain not previously immunopositive for TRH. Not all regions reactive with antiserum to [Tyr0]prepro-TRH-(25-50) were also recognized by anti-pYT, -pYS, and -pAC. These studies confirm the presence of the deduced non-TRH sequences within the TRH precursor and their formation and transport in vivo in the central nervous system. The presence of immunoreactivity in regions of the brain that do not contain TRH and the variability of immunostaining of the different antisera in some of these regions suggest regional preferential processing of pro-TRH to other peptides that may be biologically active.

Neuropeptide-Y-immunoreactive innervation of thyrotropin-releasing hormone-synthesizing neurons in the rat hypothalamic paraventricular nucleus.

The association of neuropeptide-Y (NPY)-immunoreactive (IR) axon terminals with TRH-synthesizing neurons in the rat hypothalamic paraventricular nucleus (PVN) has been studied. Immunocytochemical single and double labeling studies were performed at both light and electron microscopic levels using antiserum to NPY and, as a marker of TRH-containing neurons, antisera recognizing the N-terminal flanking peptides of the TRH prohormone, prepro-TRH-(25-50) and prepro-TRH-(53-74). At the light microscopic level, a diffuse group of TRH-IR cell bodies were observed in the anterior parvocellular subdivision of the PVN and became more numerous and densely clustered in the medial and periventricular parvocellular subdivisions. NPY-IR fibers were observed to innervate all subdivisions of the PVN, but were particularly dense in the anterior, medial, and periventricular parvocellular subdivisions of the nucleus, where they appeared to contact TRH-synthesizing perikarya and neuronal processes. At the ultrastructural level, numerous NPY-IR axon terminals containing labeled vesicles were either tightly juxtaposed to TRH-producing neurons or seen to establish both symmetric and asymmetric synaptic contacts with TRH-containing cell bodies and dendrites. Some NPY-IR axon terminals also established synaptic contacts with unlabeled PVN perikarya and processes or were found in close apposition to blood vessels. These data provide a morphological basis to suggest NPY-mediated neuroendocrine regulation over the biosynthesis and/or secretion of TRH in the PVN. Reports of the colocalization of NPY and catecholamines in the same axon terminals raises the possibility of a potential interaction between NPY and catecholamines to influence TRH neurons in the PVN. Morphological evidence for synaptic interactions between NPY-IR axon terminals and non-TRH-containing neurons in the PVN further suggests that this peptide may influence other neuroendocrine systems.

Processing of proTRH to its intermediate products occurs before the packing into secretory granules of transfected AtT20 cells.

The intracellular compartments where posttranslational processing of proTRH takes place have not been identified. Using AtT20 cells transfected with a complementary DNA for preproTRH, we have used purified antibodies that recognize the intact precursor, intermediate and end products of processing to identify the subcellular compartments in which cleavage occur. Further, pulse-chase experiments followed by subcellular fractionation were undertaken to determine the order of processing of proTRH during its transport to the secretory granules. Cells were homogenized by nitrogen cavitation and subjected to a centrifugation of 1.065 mg/ml density gradient of Percoll to separate secretory granules (SG) from rough endoplasmic reticulum (RER)/Golgi apparatus. The purity of the SG and RER fractions was assessed by assays of marker enzymes for mitochondria, RER, Golgi, and cytoplasm. ProTRH derived cryptic peptides and TRH in each fraction were determined by RIA. Golgi and SG fractions were subjected to polyacrylamide gel electrophoresis followed by extraction and RIA. Using the anti-pCC10 antiserum which recognizes intact (26 kd) as well as partially processed prohormone, the RER/Golgi fraction contained 0.3 pmol intact ProTRH and 0.2 pmol each 15 and 6 kilodalton (kDa) fragments; the SG contained the 15 kDa moiety (0.2 pmol) along with a 6 kDa (0.4 pmol) material but not the 26 kDa ProTRH. The SG were also enriched by 0.21 pmol pYE27 (PreproTRH 25-50), 0.23 pmol pFT (PreproTRH 53-74), 0.31 pmol pEH24 (PreProTRH 86-106), and 0.5 pmol TRH. None of these were present in the RER/Golgi. Pulse-chase studies also showed that the intact proTRH (26 kDa) precursor was only present in the RER/Gg fraction along with two of its N-terminal intermediate processing products, a 15 k mol wt peptide and a 6 k mol wt peptide, and two of its C-terminal processing products, a 16.5 k mol wt and a 9.6 k mol wt peptides. In addition, fully processed peptides as well as TRH were only detected in the neurosecretory granules. These observations suggest that after the initial conversion of proTRH in the RER/Golgi fraction, the peptides are delivered to the granules where processing to TRH and cryptic peptides takes place. Supporting this, our pulse-chase studies unequivocally showed that, pEH24, an end product of proTRH processing, was only produced in secretory granules. Thus, initial cleavage of the TRH precursor may be required for packing and sorting of the end products to occur.